Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Stem cell transplantation for neuroblastoma

Bone Marrow Transplantation volume 41, pages 159–165 (2008)Cite this article

Abstract

High-risk neuroblastoma is a childhood malignancy with a poor prognosis. Gradual improvements in survival have correlated with therapeutic intensity, and the ability to harvest, process and store autologous hematopoietic stem cells has allowed for dose intensification beyond marrow tolerance. The use of high-dose chemotherapy with autologous hematopoietic stem cell rescue in consolidation has resulted in improvements in survival, although further advances are still needed. Newer approaches to SCT and supportive care, most notably the transition to PBSC, have resulted in further improvement in survival and decreases in treatment-related mortality. Research into experimental approaches to hematopoietic SCT is ongoing.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Maris JM, Hogarty MD, Bagatell R, Cohn SL . Neuroblastoma. Lancet 2007; 369: 2106–2120.

    Article  CAS  Google Scholar 

  2. Cheung NV, Heller G . Chemotherapy dose intensity correlates strongly with response, median survival, and median progression-free survival in metastatic neuroblastoma. J Clin Oncol 1991; 9: 1050–1058.

    Article  CAS  Google Scholar 

  3. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N Engl J Med 1999; 341: 1165–1173.

    Article  CAS  Google Scholar 

  4. Berthold F, Boos J, Burdach S, Erttmann R, Henze G, Hermann J et al. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. Lancet Oncol 2005; 6: 649–658.

    Article  CAS  Google Scholar 

  5. George RE, Li S, Medeiros-Nancarrow C, Neuberg D, Marcus K, Shamberger RC et al. High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update. J Clin Oncol 2006; 24: 2891–2896.

    Article  Google Scholar 

  6. Grupp SA, Stern JW, Bunin N, Nancarrow C, Ross AA, Mogul M et al. Tandem high-dose therapy in rapid sequence for children with high-risk neuroblastoma. J Clin Oncol 2000; 18: 2567–2575.

    Article  CAS  Google Scholar 

  7. Kletzel M, Katzenstein HM, Haut PR, Yu AL, Morgan E, Reynolds M et al. Treatment of high-risk neuroblastoma with triple-tandem high-dose therapy and stem-cell rescue: results of the Chicago Pilot II Study. J Clin Oncol 2002; 20: 2284–2292.

    Article  CAS  Google Scholar 

  8. Kreissman SG, Rackoff W, Lee M, Breitfeld PP . High dose cyclophosphamide with carboplatin: a tolerable regimen suitable for dose intensification in children with solid tumors. J Pediatr Hematol Oncol 1997; 19: 309–312.

    Article  CAS  Google Scholar 

  9. Matthay KK . Impact of myeloablative therapy with bone marrow transplantation in advanced neuroblastoma. Bone Marrow Transplant 1996; 18 (Suppl 3): S21–S24.

    PubMed  Google Scholar 

  10. Matthay KK, O'Leary MC, Ramsay NK, Villablanca J, Reynolds CP, Atkinson JB et al. Role of myeloablative therapy in improved outcome for high risk neuroblastoma: review of recent Children's Cancer Group results. Eur J Cancer 1995; 31A: 572–575.

    Article  CAS  Google Scholar 

  11. Dini G, Philip T, Hartmann O, Pinkerton R, Chauvin F, Garaventa A et al. Bone marrow transplantation for neuroblastoma: a review of 509 cases. EBMT Group. Bone Marrow Transplant 1989; 4 (Suppl 4): 42–46.

    PubMed  Google Scholar 

  12. Philip T, Ladenstein R, Lasset C, Hartmann O, Zucker JM, Pinkerton R et al. 1070 myeloablative megatherapy procedures followed by stem cell rescue for neuroblastoma: 17 years of European experience and conclusions. European Group for Blood and Marrow Transplant Registry Solid Tumour Working Party. Eur J Cancer 1997; 33: 2130–2135.

    Article  CAS  Google Scholar 

  13. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999; 341: 1165–1173.

    Article  CAS  Google Scholar 

  14. Gazitt Y . Comparison between granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in the mobilization of peripheral blood stem cells. Curr Opin Hematol 2002; 9: 190–198.

    Article  Google Scholar 

  15. Rowley SD, Donaldson G, Lilleby K, Bensinger WI, Appelbaum FR . Experiences of donors enrolled in a randomized study of allogeneic bone marrow or peripheral blood stem cell transplantation. Blood 2001; 97: 2541–2548.

    Article  CAS  Google Scholar 

  16. Rill DR, Santana VM, Roberts WM, Nilson T, Bowman LC, Krance RA et al. Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood 1994; 84: 380–383.

    CAS  PubMed  Google Scholar 

  17. Hafer R, Voigt A, Gruhn B, Zintl F . Neuroblastoma cells can express the hematopoietic progenitor cell antigen CD34 as detected at surface protein and mRNA level. J Neuroimmunol 1999; 96: 201–206.

    Article  CAS  Google Scholar 

  18. Voigt A, Hafer R, Gruhn B, Zintl F . Expression of CD34 and other haematopoietic antigens on neuroblastoma cells: consequences for autologous bone marrow and peripheral blood stem cell transplantation. J Neuroimmunol 1997; 78: 117–126.

    Article  CAS  Google Scholar 

  19. Donovan J, Temel J, Zuckerman A, Gribben J, Fang J, Pierson G et al. CD34 selection as a stem cell purging strategy for neuroblastoma: preclinical and clinical studies. Med Pediatr Oncol 2000; 35: 677–682.

    Article  CAS  Google Scholar 

  20. Kanold J, Yakouben K, Tchirkov A, Carret AS, Vannier JP, LeGall E et al. Long-term results of CD34(+) cell transplantation in children with neuroblastoma. Med Pediatr Oncol 2000; 35: 1–7.

    Article  CAS  Google Scholar 

  21. Reynolds CP, Seeger RC, Vo DD, Black AT, Wells J, Ugelstad J . Model system for removing neuroblastoma cells from bone marrow using monoclonal antibodies and magnetic immunobeads. Cancer Res 1986; 46: 5882–5886.

    CAS  PubMed  Google Scholar 

  22. Seeger RC, Vo DD, Ugelstad J, Reynolds CP . Removal of neuroblastoma cells from bone marrow with monoclonal antibodies and magnetic immunobeads. Prog Clin Biol Res 1986; 211: 285–293.

    CAS  PubMed  Google Scholar 

  23. Kreissman SG, Villablanca JG, Diller L, London WB, Maris JM, Park R et al. Response and toxicity to a dose-intensive multi-agent chemotherapy induction regimen for high risk neuroblastoma (HR-NB): a Children's Oncology Group (COG A3973) study. J Clin Oncol 2007; 25: 9505.

    Google Scholar 

  24. Shpall EJ, Champlin R, Glaspy JA . Effect of CD34+ peripheral blood progenitor cell dose on hematopoietic recovery. Biol Blood Marrow Transplant 1998; 4: 84–92.

    Article  CAS  Google Scholar 

  25. Grupp SA, Cohn SL, Wall D, Reynolds CP . Collection, storage, and infusion of stem cells in children with high-risk neuroblastoma: saving for a rainy day. Pediatr Blood Cancer 2006; 46: 719–722.

    Article  Google Scholar 

  26. Shpall EJ, Champlin R, Glaspy JA . Effect of CD34+ peripheral blood progenitor cell dose on hematopoietic recovery. Biol Blood Marrow Transplant 1998; 4: 84–92.

    Article  CAS  Google Scholar 

  27. Linn YC, Heng KK, Rohimah S, Goh YT . Peripheral blood progenitor cell mobilization in three groups of subjects: a comparison of leukapheresis yield and timing. J Clin Apher 2000; 15: 217–223.

    Article  CAS  Google Scholar 

  28. Yu J, Leisenring W, Bensinger WI, Holmberg LA, Rowley SD . The predictive value of white cell or CD34+ cell count in the peripheral blood for timing apheresis and maximizing yield. Transfusion 1999; 39: 442–450.

    Article  CAS  Google Scholar 

  29. Philip T, Ladenstein R, Zucker JM, Pinkerton R, Bouffet E, Louis D et al. Double megatherapy and autologous bone marrow transplantation for advanced neuroblastoma: the LMCE2 study. Br J Cancer 1993; 67: 119–127.

    Article  CAS  Google Scholar 

  30. Grupp SA, Stern JW, Bunin N, Nancarrow C, Adams R, Gorlin JB et al. Rapid-sequence tandem transplant for children with high-risk neuroblastoma. Med Pediatr Oncol 2000; 35: 696–700.

    Article  CAS  Google Scholar 

  31. Powell JL, Bunin NJ, Callahan C, Aplenc R, Griffin G, Grupp SA . An unexpectedly high incidence of Epstein–Barr virus lymphoproliferative disease after CD34+ selected autologous peripheral blood stem cell transplant in neuroblastoma. Bone Marrow Transplant 2004; 33: 651–657.

    Article  CAS  Google Scholar 

  32. Matthay KK, Yanik G, Messina J, Quach A, Huberty J, Cheng SC et al. Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma. J Clin Oncol 2007; 25: 1054–1060.

    Article  CAS  Google Scholar 

  33. Matthay KK, DeSantes K, Hasegawa B, Huberty J, Hattner RS, Ablin A et al. Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma. J Clin Oncol 1998; 16: 229–236.

    Article  CAS  Google Scholar 

  34. Klingebiel T, Bader P, Bares R, Beck J, Hero B, Jurgens H et al. Treatment of neuroblastoma stage 4 with 131I-meta-iodo-benzylguanidine, high-dose chemotherapy and immunotherapy. A pilot study. Eur J Cancer 1998; 34: 1398–1402.

    Article  CAS  Google Scholar 

  35. Yanik GA, Levine JE, Matthay KK, Sisson JC, Shulkin BL, Shapiro B et al. Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma. J Clin Oncol 2002; 20: 2142–2149.

    Article  CAS  Google Scholar 

  36. Cheung NK, Kushner BH, Kramer K . Monoclonal antibody-based therapy of neuroblastoma. Hematol Oncol Clin North Am 2001; 15: 853–866.

    Article  CAS  Google Scholar 

  37. Osenga KL, Hank JA, Albertini MR, Gan J, Sternberg AG, Eickhoff J et al. A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group. Clin Cancer Res 2006; 12: 1750–1759.

    Article  CAS  Google Scholar 

  38. Kushner BH, Kramer K, Cheung N-KV . Phase II trial of the anti-GD2 monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma. J Clin Oncol 2001; 19: 4189–4194.

    Article  CAS  Google Scholar 

  39. Simon T, Hero B, Faldum A, Handgretinger R, Schrappe M, Niethammer D et al. Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma. J Clin Oncol 2004; 22: 3549–3557.

    Article  CAS  Google Scholar 

  40. Srinivasan R, Barrett J, Childs R . Allogeneic stem cell transplantation as immunotherapy for nonhematological cancers. Semin Oncol 2004; 31: 47–55.

    Article  Google Scholar 

  41. Matthay KK, Seeger RC, Reynolds CP, Stram DO, O'Leary MC, Harris RE et al. Allogeneic versus autologous purged bone marrow transplantation for neuroblastoma: a report from the Childrens Cancer Group. J Clin Oncol 1994; 12: 2382–2389.

    Article  CAS  Google Scholar 

  42. Gratwohl A, Baldomero H, Demirer T, Rosti G, Dini G, Ladenstein R et al. Hematopoetic stem cell transplantation for solid tumors in Europe. Ann Oncol 2004; 15: 653–660.

    Article  CAS  Google Scholar 

  43. Inoue M, Nakano T, Yoneda A, Nishikawa M, Nakayama M, Yumura-Yagi K et al. Graft-versus-tumor effect in a patient with advanced neuroblastoma who received HLA haplo-identical bone marrow transplantation. Bone Marrow Transplant 2003; 32: 103–106.

    Article  CAS  Google Scholar 

  44. Marabelle A, Paillard C, Tchirkov A, Halle P, Chassagne J, Demeocq F et al. Graft-versus-tumour effect in refractory metastatic neuroblastoma. Bone Marrow Transplant 2007; 39: 809–810.

    Article  CAS  Google Scholar 

  45. Yamashiro DJ, Lee A, Bhatia M, Glade-Bender J, Qualter E, Militano O et al. Feasibility of autologous stem cell transplant followed by reduced intensity allogeneic stem cell transplantation for high risk neuroblastoma: a single institution pilot study. Biol Blood Marrow Transplant 2007; 13: 68–69.

    Article  Google Scholar 

  46. Toro GD, Bradley M, Satwani P, Morris E, Ven Cvd, Cheung YK et al. Reduced intensity (RI) allogeneic cord blood hematopoietic cell transplantation (Allo CBHCT) in pediatric patients with malignant and non-malignant diseases. Biol Blood Marrow Transplant 2006; 12: 125.

    Article  Google Scholar 

  47. Seeger RC, Reynolds CP, Gallego R, Stram DO, Gerbing RB, Matthay KK . Quantitative tumor cell content of bone marrow and blood as a predictor of outcome in stage IV neuroblastoma: a Children's Cancer Group Study. J Clin Oncol 2000; 18: 4067–4076.

    Article  CAS  Google Scholar 

  48. Katzenstein HM, Cohn SL, Shore RM, Bardo DM, Haut PR, Olszewski M et al. Scintigraphic response by 123I-metaiodobenzylguanidine scan correlates with event-free survival in high-risk neuroblastoma. J Clin Oncol 2004; 22: 3909–3915.

    Article  Google Scholar 

  49. Matthay KK, Edeline V, Lumbroso J, Tanguy ML, Asselain B, Zucker JM et al. Correlation of early metastatic response by 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma. J Clin Oncol 2003; 21: 2486–2491.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA, USA

    J D Fish & S A Grupp

  2. Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, PA, USA

    S A Grupp

  3. Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, Philadelphia, PA, USA

    S A Grupp

Authors
  1. J D Fish
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S A Grupp
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S A Grupp.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fish, J., Grupp, S. Stem cell transplantation for neuroblastoma. Bone Marrow Transplant 41, 159–165 (2008). https://doi.org/10.1038/sj.bmt.1705929

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705929

Keywords

This article is cited by

Search

Advanced search

Quick links